Skip to main content
OpenTrials
Completed

NCT Number: NCT05851638

The NIOMI Study: Non-Invasive Lung Oxygen Monitoring of Term Infants

Infants born prematurely e.g. before 28 weeks of gestational age have a 50% chance of developing neonatal respiratory distress syndrome (NRDS). The management of NRDS is currently driven by information obtained from a sampling of arterial blood, pulse oximetry, and x-ray imaging. On the other hand, these tests carry short and long-term negative outcomes for vulnerable patients. Optical technology has been developed to evaluate lung function non-invasively and without any potential risks for the patients. It is based on Gas in Scattering Media Absorbance Spectroscopy (GASMAS) method, using low-power laser light and a photodetector attached directly to the baby's torso.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 7 day

Sex eligibility

All sexes

Study type

Observational

Primary location

Cork University Maternity Hospital

Cork, Ireland

About this study

The purpose of this observational study is to test a non-invasive, optical system designed to directly measure the oxygen within the lungs of neonates using a GASMAS system (NEOLA-alpha 2, GPX medical). The findings of this study will generate the necessary information that will be used to guide the development of the GASMAS-based systems for future clinical adaptation in preterm infants.

Subjects. The measurements will be performed on full-term (gestational age ≥37 weeks), healthy infants after parental consent has been obtained.

Number of participants to be recruited: 100

Data collection. This will be a prospective study. Relevant data will be collected from maternal and neonatal electronic chart records.

Procedure. A specially designed light source probe (2x2cm size) with 2x incorporated laser sources and a detector probe (2x2cm size) will be attached to the torso of the infant in a total of 10 locations (5 for the left side of the chest and 5 for the right side) to measure lung oxygen.

Locations of the probes. The measurements will be recorded with the detector probe placed in the infant's armpit and the light source probe placed at the locations indicated below:

  • 2nd intercostal space in midclavicular line;
  • 4th intercostal space in midclavicular line (beside the level of nipple);
  • 6th intercostal space in midclavicular line;
  • 1.5 cm below detector probe in midaxillary line;
  • parasternally beside inferior angle of scapula.

Duration. A single optical measurement lasts approximately 2 minutes. The entire measurement session will be aimed to be completed in 30 minutes. Same measurements will be obtained daily until baby will be discharged from the hospital.

Special conditions. This is a painless procedure that should not carry any risks for the baby.

Location. Procedure will be performed in a separate monitoring room on the postnatal ward in Cork University Maternity hospital (CUMH), where parental and infant comfort as well as appropriate handling of technique can be ensured.

Safety measures Materials. The components of the GASMAS system that will be in contact with the infant's skin have been fabricated from non-toxic materials. They were also designed to be as comfortable as possible without any sharp corners or features.

Eye safety. The emission from the light source probe at all wavelengths is weak and diffuse and falls under "Laser Class I" category. Lasers of this category are considered safe and present no hazard to the eye or the skin under direct exposure. There is no need to wear any eye protection for anyone involved in the measurements.

Electrical safety. The system is well shielded and safe to use. Leak currents are tested according to standard 60601. The system has been tested to comply with Radiated Emission Test according to standard EN 55032 Class A.

Mechanical safety. The medical cart is tested to UL/EN/IEC and FCC Part 15 Class A specifications for enhanced patient safety. The medical cart is environmentally clean with RoHS, REACH, WEEE and EU (94/62/EC) packaging compliance.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy infant on the postnatal ward.
  • Full-term (gestational age ≥37 weeks).
  • Anticipated stay in the hospital > 1 day.

Exclusion criteria

  • Parent/guardian unable to/declined to participate in the study.
  • The baby was admitted to the Neonatal Unit.
  • Presence of congenital cardiac anomalies (report of antenatal scans from patient electronic record chart)

Treatment and study plan

Lung Oxygen measurement with GASMAS system

Device

A specially designed light source probe (2x2cm size) with 2x incorporated laser sources and a detector probe (2x2cm size) will be attached to the torso of the infant in a total of 10 locations to measure lung oxygen.

Primary outcomes

  1. Percentage of infants in whom at least 1 oxygen measurement was obtained.

    Time frame: 12 months

    The primary outcome will be the percentage of infants in whom at least 1 oxygen measurement was obtained where the signal-to-noise ratio was greater than 3.

  2. Projected concentration in percent meters

    Time frame: 12 months

    Describe the absorption of water vapor and molecular oxygen, by means of projected concentration, presented in percent meters (%m)

Sponsors and collaborators

Lead sponsor

University College Cork

Other

Collaborators

  • Tyndall National Institute

Registry information

Acronym: NIOMI

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
May 10, 2023
Registry last updated
May 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.